Frequency-domain analysis of the QRS complex after treatment of childhood cancer with anthracycline cytostatics

Pediatric Cardiology

Volumn 22, Issue 6, 2001, Pages 478-482

  Mladosievicova, B ^a   Foltinova, A ^b   Luptak, I ^a   Petrasova, H ^a   Hulin, I ^a  

^a Faculty of Medicine of Comenius University and University Hospital Bratislava   (Slovakia)

^b University Children's Hospital Bratislava   (Slovakia)

Author keywords

Anthracycline cardiotoxicity; Fast Fourier transform; Late effects; Signal averaged electrocardiography

Indexed keywords

ANTHRACYCLINE; CYTOSTATIC AGENT; DAUNORUBICIN; DOXORUBICIN;

ADOLESCENT; ADULT; ARTICLE; CARDIOTOXICITY; CHILD; CHILDHOOD CANCER; CONTROLLED STUDY; ELECTROCARDIOGRAM; FEMALE; FOURIER TRANSFORMATION; HEART DISEASE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MYOCARDIAL DISEASE; QRS COMPLEX; SIGNAL AVERAGED ELECTROCARDIOGRAPHY;

ADOLESCENT; ADULT; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CHILD; ELECTROCARDIOGRAPHY; FEMALE; HEART; HUMANS; MALE; SIGNAL PROCESSING, COMPUTER-ASSISTED; STATISTICS, NONPARAMETRIC;

EID: 0035209431     PISSN: 01720643     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002460010278     Document Type: Article

References (30)

1. Anthracycline cardiomyopathy monitored by morphological changes
2. Signal-averaged electrocardiography
3. Ventricular late potentials in the assessment of mitoxantrone cardiotoxicity
4. Review of tests for monitoring doxorubicin-induced cardiomyopathy
5. Anthracycline cardiotoxicity, no longer an issue?
6. Gliding window fast Fourier transform analysis: A new method for discovering the contribution of higher frequencies in signal-averaged ECG
7. Usefulness of signal-averaged electrocardiogram in dilated cardiomyopathy for identifying patients with ventricular arrhythmias
8. Suitable analyzed signal duration and criteria for abnormal signal-averaged electrocardiogram on frequency-domain analysis in patients with Duchenne's muscular dystrophy
9. Electrocardiograph changes and arrhythmias after cancer therapy in children and young adults
10. The use of echocardiography and Holter monitoring in the assessment of anthracycline treated patients
11. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood
12. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer
13. Detection of anthracycline-induced cardiotoxicity
14. Signal-averaged ECG in the evaluation of anthracycline cardiotoxicity in survivors of childhood cancer
15. Late effects of anthracycline therapy in childhood on signal-averaged ECG parameters
16. Signal-averaged ECG in patients after anthracyctine therapy for childhood cancer
17. Time-frequency mapping of the QRS complex in normal subjects and in postmyocardial infarction patients
18. Late cardiotoxicity following anthracycline therapy for childhood cancer
19. Late cardiotoxicity after treatment for a malignant bone tumor
20. Anthracycline-induced cardiotoxicity
21. Adriamycin cardiomyopathy: Pathophysiology and prevention
22. Doxorubicin-induced cardiomyopathy
23. Gliding-window fast Fourier transform analysis of the entire QRS complex and the distribution of area ratio peaks in healthy subjects and patients with myocardial infarction
24. Cardiac status of 42 patients more than 15 years post anthracyclinc therapy
25. Cardiac failure and dyarrhythmias 6-19 years after anthracycline therapy: A series of 15 patients
26. Cardiac toxicity 4 to 20 years after completing anthracycline therapy
27. Guidelines for cardiac monitoring of children during and after anthracycline therapy: Report of the Cardiology Committee of the Children's Cancer Study Group
28. Ventricular late potentials: Another expression of cardiotoxicity of cytostatic drugs in children?
29. The anthracyclines: Will we ever find a better doxorubicine?
30. Prognostic significance of spectral turbulence analysis of the signal-averaged electrocardiogram in patients with idiopathic dilated cardiomyopathy